Relation
Relation Therapeutics is an end-to-end biotech company focused on developing transformational medicines by leveraging high-resolution biology, machine learning, and clinical insights. Their core technology, the Lab-in-the-Loop, integrates single-cell analysis, genomics, and machine learning to understand human biology and discover therapies for devastating diseases. The company, founded in January 2020, has secured significant funding, including a $60M seed round and a strategic partnership with GSK, and is actively seeking world-class talent across biology, machine learning, and drug discovery.
Relation
Relation Therapeutics is an end-to-end biotech company focused on developing transformational medicines by leveraging high-resolution biology, machine learning, and clinical insights. Their core technology, the Lab-in-the-Loop, integrates single-cell analysis, genomics, and machine learning to understand human biology and discover therapies for devastating diseases. The company, founded in January 2020, has secured significant funding, including a $60M seed round and a strategic partnership with GSK, and is actively seeking world-class talent across biology, machine learning, and drug discovery.
TL;DR
What they do: End-to-end biotech using single-cell multi-omics, functional assays and machine learning to discover medicines
Founding: Founded Jan 2020 by Charles Roberts, Benjamin Swerner, and Jake Taylor-King
Funding signal: Multiple seed rounds including a $35M seed announced Mar 14, 2024 and larger seed activity through 2024–2025
Headquarters: Regent's Place, 338 Euston Road, London NW1 3BG, UK
Related Companies
| Company |
|---|
 |
 |
 |
 |
 |
Company Overview
Problem Domain
Human-focused drug discovery for complex diseases (early indication work includes osteoporosis).
Founded
2019
Industry
Biotechnology Research
Tech Stack
Funding Track Record
35000000
Seed round announced Mar 14, 2024
25000000
Reported $25M round in June 2022
Seed led by Magnetic Ventures (July 2021) per company timeline
Investor Signal
“DCVC, Magnetic Ventures, Khosla Ventures, Firstminute Capital, NVentures, ARK Investment Management, Deerfield Management, NVIDIA, Hitachi Investments, Ark Invest”